000157421 001__ 157421
000157421 005__ 20240229123137.0
000157421 0247_ $$2doi$$a10.1186/s13014-020-01625-0
000157421 0247_ $$2pmid$$apmid:32758267
000157421 0247_ $$2pmc$$apmc:PMC7405378
000157421 0247_ $$2altmetric$$aaltmetric:87231686
000157421 037__ $$aDKFZ-2020-01616
000157421 041__ $$aeng
000157421 082__ $$a610
000157421 1001_ $$aHeld, Thomas$$b0
000157421 245__ $$aCarbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial.
000157421 260__ $$aLondon$$bBioMed Central$$c2020
000157421 3367_ $$2DRIVER$$aarticle
000157421 3367_ $$2DataCite$$aOutput Types/Journal article
000157421 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1600155382_30781
000157421 3367_ $$2BibTeX$$aARTICLE
000157421 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157421 3367_ $$00$$2EndNote$$aJournal Article
000157421 500__ $$a#LA:E050#
000157421 520__ $$aIntensity-modulated re-radiotherapy (reIMRT) has been established as a standard local treatment option in patients with non-resectable, recurrent head and neck cancer (rHNC). However, the clinical outcome is unfavorable and severe toxicities (≥grade III) occurred in 30-40% of patients. The primary aim of the current trial is to investigate carbon ion reirradiation (reCIRT) compared to reIMRT in patients with rHNC regarding safety/toxicity as well as local control, overall survival (OS), and quality of life (QoL).The present trial will be performed as a single center, two-armed, prospective phase II study. A maximum of 72 patients will be treated with either reIMRT or reCIRT to evaluate severe (≥grade III) treatment-related toxicities (randomization ratio 1:1). The primary target value is to generate less than 35% acute/subacute severe toxicity (≥grade III), according to the Common Terminology Criteria for Adverse Events v5.0, within 6 months after study treatment. The total dose of reirradiation will range between 51 and 60 Gy or Gy (RBE), depending primarily on the radiotherapy interval and the cumulative dose to organs at risk. Individual dose prescription will be at the discretion of the treating radiation oncologist. The local and distant progression-free survival 12 months after reirradiation, the OS, and the QoL are the secondary endpoints of the trial. Explorative trial objectives are the longitudinal investigation of clinical patient-related parameters, tumor parameters on radiological imaging, and blood-based tumor analytics.Recent retrospective studies suggested that reCIRT could represent a feasible and effective treatment modality for rHNC. This current randomized prospective trial is the first to investigate the toxicity and clinical outcome of reCIRT compared to reIMRT in patients with rHNC.ClinicalTrials.gov ; NCT04185974 ; December 4th 2019.
000157421 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000157421 588__ $$aDataset connected to CrossRef, PubMed,
000157421 7001_ $$aLang, Kristin$$b1
000157421 7001_ $$aRegnery, Sebastian$$b2
000157421 7001_ $$aWeusthof, Katharina$$b3
000157421 7001_ $$aHommertgen, Adriane$$b4
000157421 7001_ $$aJäkel, Cornelia$$b5
000157421 7001_ $$aTonndorf-Martini, Eric$$b6
000157421 7001_ $$aKrisam, Johannes$$b7
000157421 7001_ $$aPlinkert, Peter$$b8
000157421 7001_ $$aZaoui, Karim$$b9
000157421 7001_ $$aFreudlsperger, Christian$$b10
000157421 7001_ $$aMoratin, Julius$$b11
000157421 7001_ $$aKrauss, Jürgen$$b12
000157421 7001_ $$0P:(DE-HGF)0$$aHarrabi, Semi B$$b13
000157421 7001_ $$0P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aHerfarth, Klaus$$b14$$udkfz
000157421 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b15$$udkfz
000157421 7001_ $$00000-0001-8463-514X$$aAdeberg, Sebastian$$b16$$eLast author
000157421 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/s13014-020-01625-0$$gVol. 15, no. 1, p. 190$$n1$$p190$$tRadiation oncology$$v15$$x1748-717X$$y2020
000157421 909CO $$ooai:inrepo02.dkfz.de:157421$$pVDB
000157421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000157421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000157421 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000157421 9101_ $$0I:(DE-588b)2036810-0$$60000-0001-8463-514X$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000157421 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000157421 9141_ $$y2020
000157421 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-01-12
000157421 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-12
000157421 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-12
000157421 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000157421 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000157421 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000157421 980__ $$ajournal
000157421 980__ $$aVDB
000157421 980__ $$aI:(DE-He78)E050-20160331
000157421 980__ $$aI:(DE-He78)HD01-20160331
000157421 980__ $$aUNRESTRICTED